Origin

Synthesized by the St. Petersburg Institute of Bioregulation and Gerontology as an immune-targeted bioregulator, part of the Khavinson family aimed at modulating tissue-specific immune function.

Mechanism

Proposed to activate B-cell populations in the spleen by affecting proliferation and apoptosis regulation.

Research summary

Evidence

A 2014 paper found Crystagen activates immune B-cells by modulating apoptosis, with a narrower overall cell-renewal effect than other family members like Vilon. The research base is small and mostly confined to Russian-language literature from the St. Petersburg Institute, with little independent Western replication.

Evidence tier: Approved in Russia; limited Western literature — see the methodology note for how this is assessed.

Citations

Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process — Khavinson et al. 2014

Reported benefits

claimed B-cell immune activation
claimed enhanced immune response in aging
claimed reduced immune senescence

Dosing protocols reported in the literature & community

These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.

Reported dosing protocols
Route	Reported protocol
Subcutaneous injection	Community reports: 10-20 mg daily for 10-20 days, repeated every 3-6 months.

Side effects

generally well tolerated
localized injection-site reactions possible

Safety notes

Community & reddit notes (anecdotal — not clinical evidence)

Community reports suggest immune-support benefits, often stacked with Vilon or Thymalin, entirely anecdotal.